ST Pharm Posts 26.4 Billion Won Operating Profit in Q4...Annual Figure Nearly Doubles

Oligo CDMO Sales Grow 35%...Annual Revenue Reaches 331.6 Billion Won

ST Pharm announced on the 9th that, on a consolidated basis, it posted sales of 129.0 billion won and operating profit of 26.4 billion won in the fourth quarter of last year. Compared with the same period a year earlier, sales increased by 11.4% and operating profit by 15.9%. Net profit for the period came to 31.0 billion won, up 148.9%.

Overview of ST Pharm Banwol Plant. ST Pharm

Annual sales for last year were 331.6 billion won, an increase of 21.1% year-on-year. Operating profit rose 98.9% to 55.1 billion won, and net profit increased 67.9% to 54.5 billion won.

The oligonucleotide business division recorded annual sales of 237.6 billion won last year, growing 35.0% from a year earlier. Fourth-quarter sales were 87.9 billion won. Of the annual sales, 174.4 billion won, or 73% of the total, came from commercialized projects. As of the end of last year, the oligonucleotide order backlog was about 204.0 billion won. In January this year, the company additionally secured a new single-supply contract worth 83.0 billion won.

The small-molecule division posted annual sales of 26.3 billion won, up 2.3% year-on-year. Fourth-quarter sales were 18.4 billion won. As of the end of last year, the order backlog in this division was about 77.0 billion won. The messenger RNA (mRNA) division recorded annual sales of 3.1 billion won, with fourth-quarter sales of 400 million won.

Annual sales in other segments, including CRO, were 38.5 billion won, an increase of 29.7% from a year earlier. Fourth-quarter sales were 12.9 billion won. The company stated that the operating loss in this segment decreased compared with the previous year.

A representative of ST Pharm said, "Our CDMO clients are scheduled to obtain NDA and sNDA approvals and to announce top-line and interim clinical data in 2026," adding, "Our internally developed AIDS treatment candidate STP-0404 is currently in a global Phase 2a clinical trial, and we plan to announce the final top-line results in the second or third quarter of 2026."

This content was produced with the assistance of AI translation services.